What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide — a chain of nine amino acids — first isolated from the diencephalon of rabbits in the early 1970s. It is one of the most extensively studied sleep peptides in early clinical and preclinical research, with properties that extend well beyond simple sleep induction.
Unlike conventional hypnotics that broadly suppress brain activity, DSIP works by modulating circadian rhythms and the natural architecture of sleep, specifically promoting slow-wave sleep phases (delta sleep) — the deepest, most anabolic and restorative stages of the nightly cycle.
The peptide is naturally produced in the hypothalamus and pituitary gland, with plasma concentrations following a circadian pattern: levels peak during the early nighttime hours. This makes DSIP a physiologically coherent candidate for those seeking to support sleep quality through endogenous mechanisms rather than pharmacological suppression.
Mechanism of Action
DSIP acts across multiple axes of the central and peripheral nervous system:
Delta sleep promotion: The peptide acts on the hypothalamus and pituitary to facilitate the transition into slow-wave sleep (N3 stages of NREM sleep). This is the sleep phase most associated with growth hormone secretion, memory consolidation, and tissue repair.
Nocturnal GH secretion support: By deepening and prolonging delta sleep, DSIP indirectly favors the nocturnal GH pulses that occur during slow-wave sleep. Direct effects on GH release independent of sleep have also been described in the literature.
Cortisol reduction: DSIP exerts modulatory effects on the hypothalamic-pituitary-adrenal (HPA) axis, attenuating nighttime cortisol secretion. Elevated nocturnal cortisol is among the most common causes of fragmented, non-restorative sleep.
Adaptogenic properties: DSIP exhibits adaptogenic characteristics by reducing physical and oxidative stress responses. Animal model studies have demonstrated protection against oxidative cellular damage and improved stress tolerance.
Antioxidant activity: Reductions in systemic oxidative stress markers have been documented, with potential implications for athletic recovery, cellular aging, and general metabolic health.
Reported Usage Protocol
⚠️ The following information is strictly educational and describes protocols used in research contexts. It does not constitute a prescription or medical recommendation.
| Week | Dose | Route | Timing |
|---|---|---|---|
| 1-2 | 100 mcg/night | SC | 30-60 min before sleep |
| 3-8 | 200-300 mcg/night | SC | 30-60 min before sleep |
Reconstitution of 5 mg vial: Add 2.5 mL bacteriostatic water (BAC water) → resulting concentration: 2 mg/mL (2000 mcg/mL).
- 100 mcg dose = 0.05 mL (5 units on U-100 insulin syringe)
- 200 mcg dose = 0.10 mL (10 units)
- 300 mcg dose = 0.15 mL (15 units)
Vial storage: lyophilized at -20°C; reconstituted under refrigeration (2-8°C) for up to 30 days.
Practical note: Due to its short half-life (~60 min) and physiological sedative effect, DSIP should be administered shortly before bed. Do not drive or operate machinery after the nighttime injection.
Reported Effects
Researchers and users in biohacking contexts report the following effects with DSIP:
- Deep, restorative delta sleep: Increased time in N3 phase, subjectively more restorative sleep and clearer waking.
- Nocturnal cortisol reduction: Less stress-axis activation during the night, supporting recovery.
- GH nocturnal support: Potential synergism with other GH secretagogue peptides (CJC-1295, Ipamorelin) by deepening the sleep window during which the largest GH pulse occurs.
- Adaptogenic properties: Reduced sense of accumulated fatigue, improved tolerance to chronic stress.
- Oxidative stress reduction: Lower markers of cellular damage in research models.
Reported Adverse Effects
DSIP has a generally favorable safety profile in available studies:
- Mild dizziness possible, especially with initial doses — caution when getting up.
- Excessive drowsiness in sensitive individuals at higher doses.
- No severe adverse effects reported in early-phase clinical studies at physiological doses.
- Do not drive or operate heavy machinery after the nighttime injection.
- Long-term safety data is limited given its status as a research compound.
Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (powder) | -20°C | Up to 24 months |
| Reconstituted | 2-8°C (refrigeration) | Up to 30 days |
Do not freeze the reconstituted vial. Protect from direct light. Verify the liquid is clear and colorless before each use.
Disclaimer: This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.
Reported protocol (research reference)
| Vial sizes | 5 mg |
|---|---|
| Reported dose | 100 mcg/night weeks 1-2; 200-300 mcg/night weeks 3-8, SC 30-60 min before sleep |
| Half-life | ~60 minutes |
| FDA status | Not FDA approved |